Alcolic liver disease: what’s new in the current decade?

Alcoholic liver disease (ALD) - damage to the liver parenchyma under the influence of ethanol consumption, which can manifest itself in several ways: steatosis, alcoholic hepatitis (steatohepatitis), fibrosis and cirrhosis of the liver. The present review considers publications of recent years (2020-2023) in the Pubmed and Scopus information databases devoted to the study of various aspects of the current state of the problem of alcohol-associated liver pathology. New data on the epidemiology and burden of ALD have been obtained; the pandemic of a new coronavirus infection has had a certain impact on the course of ALD. The study of individual links in the pathogenesis of ALD is actively continuing, a large number of publications are devoted to the participation and role in the pathogenesis of alcohol-associated liver diseases of the “gut-liver” axis. New therapeutic strategies for alcohol-associated liver disease are classified based on their mode of action: (1) anti-inflammatory therapies, (2) antioxidants, (3) therapies that modulate the gut-liver axis, and (4) therapies that enhance liver regeneration. At the same time, the often unfavorable prognosis and insufficient effectiveness of therapy require further study of alcohol-associated liver diseases.

alcohol, liver, alcoholic liver disease, steatosis, alcoholic hepatitis, fibrosis, cirrhosis, severe alcoholic hepatitis, acute chronic liver failure, epidemiology, disease burden, novel coronavirus infection (COVID-19), pathogenesis, treatment

1. Lazebnik L. B., Golovanova E. V., Tarasova L. V., et al. Adult Alcoholic Liver Disease. Experimental and Clinical Gastroenterology. 2020;174(2): 4-28. (In Russ.) doi: 10.31146/1682-8658-ecg-174-2-4-28.@@ Лазебник Л. Б., Голованова Е. В., Тарасова Л. В., и соавт. Алкогольная болезнь печени (АБП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020; 2 (174): 4-28. doi: 10.31146/1682-8658-ecg-174-2-4-28.

2. Federal clinical guidelines “Alcoholic liver disease (ALD) in adults”. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation on December 29, 2021. (In Russ.)@@ Федеральные клинические рекомендации «Алкогольная болезнь печени (АБП) у взрослых». Одобрено Научно-практическим Советом Минздрава РФ 29.12.2021.

3. Park S. H., Kim D. J. Global and regional impacts of alcohol use on public health: emphasis on alcohol policies. Clin Mol Hepatol. 2020 Oct;26(4):652-661. doi: 10.3350/cmh.2020.0160.

4. Addolorato G., Abenavoli L., Dallio M., et al. Alcohol associated liver disease 2020: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2020 Apr;52(4):374-391. doi: 10.1016/j.dld.2019.12.008.

5. Rehm J. The risks associated with alcohol use and alcoholism. Alcohol Res Health. 2011;34:135-43. PMID: 22330211; PMCID: PMC3307043.

6. Aslam A., Kwo P. Y. Epidemiology and Disease Burden of Alcohol Associated Liver Disease. J Clin Exp Hepatol. 2023 Jan-Feb;13(1):88-102. doi: 10.1016/j.jceh.2022.09.001.

7. Kezer C. A., Simonetto D. A., Shah V. H. Sex Differences in Alcohol Consumption and Alcohol-Associated Liver Disease. Mayo Clin Proc. 2021 Apr;96(4):1006-1016. doi: 10.1016/j.mayocp.2020.08.020.

8. Wong T., Dang K., Ladhani S., et al. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016. JAMA. 2019 May 7;321:1723-1725. doi: 10.1001/jama.2019.2276.

9. Dang K., Hirode G., Singal A. K., et al. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases. Am J Gastroenterol. 2020 Jan;115:96-104. doi: 10.14309/ajg.0000000000000380.

10. Parker R., Aithal G. P., Becker U., et al. Natural history of histologically proven alcohol-related liver disease: a systematic review. J Hepatol. 2019 Sep;71:586-593. doi: 10.1016/j.jhep.2019.05.020.

11. Clemente-Sánchez A., Oliveira-Mello A., Bataller R. Moderate Alcoholic Hepatitis. Clin Liver Dis. 2021 Aug;25(3):537-555. doi: 10.1016/j.cld.2021.03.001.

12. Van Melkebeke L., Korf H., Tsochatzis E. A., et al.Treatment of severe alcoholic hepatitis: A systematic review. Curr Opin Pharmacol. 2021 Oct;60:91-101. doi: 10.1016/j.coph.2021.06.011.

13. Singal A. K., Mathurin P. Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review. JAMA. 2021 Jul 13;326(2):165-176. doi: 10.1001/jama.2021.7683.

14. Sepanlou S. G., Safiri S., Bisignano C., et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Mar 1;5:245-266. doi: 10.1016/S2468-1253(19)30349-8.

15. Tapper E. B., Parikh N. D. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ. 2018 Jul 18;362: k2817. doi: 10.1136/bmj.k2817.

16. Younossi Z. M., Stepanova M., Younossi Y., et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020 Mar;69:564-568. doi: 10.1136/gutjnl-2019-318813

17. Shirazi F., Singal A. K., Wong R. J. Alcohol-associated cirrhosis and alcoholic hepatitis hospitalization trends in the United States. J Clin Gastroenterol. 2021 Feb 1;55:174-179. doi: 10.1097/MCG.0000000000001378.

18. Rutledge S. M., Im G. Y. Current and Future Biomarkers in Alcoholic Hepatitis. Clin Liver Dis. 2021 Aug;25(3):493-516. doi: 10.1016/j.cld.2021.03.010.

19. Ballester M. P., Sittner R., Jalan R. Alcohol and Acute-on-Chronic Liver Failure. J Clin Exp Hepatol. 2022 Sep-Oct;12(5):1360-1370. doi: 10.1016/j.jceh.2021.12.010.

20. Moreau R., Gao B., Papp M., et al. Acute-on-chronic liver failure: A distinct clinical syndrome. J Hepatol. 2021 Jul;75 Suppl 1: S27-S35. doi: 10.1016/j.jhep.2020.11.047.

21. Bajaj J. S., O’Leary J.G., Lai J. C., et al.Acute-on-Chronic Liver Failure Clinical Guidelines. Am J Gastroenterol. 2022 Feb 1;117(2):225-252. doi: 10.14309/ajg.0000000000001595.

22. Rehm J., Shield K. D. Global burden of AUDs and alcohol liver disease. Biomedicines. 2019 Dec 13;7:99. doi: 10.3390/biomedicines7040099.

23. Thompson J. A., Martinson N., Martinson M. Mortality and costs associated with alcoholic hepatitis: a claims analysis of a commercially insured population. Alcohol. 2018 Sep;71:57-63. doi: 10.1016/j.alcohol.2018.02.003.

24. Deutsch-Link S., Curtis B., Singal A. K. COVID-19 and alcohol associated liver disease. Dig Liver Dis. 2022 Nov;54(11):1459-1468. doi: 10.1016/j.dld.2022.07.007.

25. Ristic-Medic D., Petrovic S., Arsic A., Vucic V. Liver disease and COVID-19: the link with oxidative stress, antioxidants and nutrition. World J Gastroenterol. 2021 Sep 14;27:5682-5699. doi: 10.3748/wjg.v27.i34.5682.

26. Rutledge S. M., Schiano T. D., Florman S., Im G. Y. COVID-19 aftershocks on alcohol-associated liver disease: an early cross-sectional report from the U. S. Epicenter. Hepatol Commun. 2021 Jul;5:1151-1155. doi: 10.1002/hep4.1706.

27. Testino G. Are patients with AUDs at increased risk for COVID-19 infection? Alcohol Alcohol. 2020 Jun 25;55(4):344-346. doi: 10.1093/alcalc/agaa037.

28. Bramness J. G., Bye E. K., Moan I. S., Rossow I. Alcohol use during the COVID-19 pandemic: self-reported changes and motives for change. Eur Addiction Res. 2021;27:257-262. doi: 10.1159/000515102.

29. Sohal A., Khalid S., Green V., et al.The Pandemic Within the Pandemic: Unprecedented Rise in Alcohol-related Hepatitis During the COVID-19 Pandemic. J Clin Gastroenterol. 2022 Mar 1;56(3): e171-e175. doi: 10.1097/MCG.0000000000001627.

30. Bonny-Noach H., Cohen-Louck K., Levy I. Substances use between early and later stages of the COVID-19 pandemic in Israel. Isr J Health Pol Res. 2021 Aug 12;10:46. doi: 10.1186/s13584-021-00484-8.

31. Killgore W. D.S., Cloonan S. A., Taylor E. C., et al. Alcohol dependence during COVID-19 lockdowns. Psychiatr Res. 2021 Feb;296:113676. doi: 10.1016/j.psychres.2020.113676.

32. White A. M. Gender differences in the epidemiology of alcohol use and related harms in the United States. Alcohol Res Curr Rev. 2020;40, 01. doi: 10.35946/arcr.v40.2.01.

33. Zipursky J. S., Stall N. M., Silverstein W. K., et al. Alcohol sales and alcohol-related emergencies during the COVID-19 pandemic. Ann Intern Med. 2021 Jul;174:1029-1032. doi: 10.7326/M20-7466.

34. Kar.P, Tomfohr-Madsen L., Giesbrecht G., et al. Alcohol and substance use in pregnancy during the COVID-19 pandemic. Drug Alcohol Depend. 2021 Aug 1;225108760. doi: 10.1016/j.drugalcdep.2021.108760.

35. Naughton F., Ward E., Khondoker M., et al. Health behaviour change during the UK COVID-19 lockdown: findings from the first wave of the C-19 health behaviour and well-being daily tracker study. Br J Health Psychol. 2021 May;26:624-643. doi: 10.1111/bjhp.12500.

36. Chartier K. G., Guidry J. P.D., Lee C. A., Buckley T. D. At home and online during the early months of the COVID-19 pandemic and the relationship to alcohol consumption in a national sample of U.S. adults. PLoS One. 2021;16e0259947. doi: 10.1371/journal.pone.0259947.

37. Sidor A., Rzymski P. Dietary choices and habits during COVID-19 lockdown: experience from Poland. Nutrients. 2020 Jun 3;12(6):1657. doi: 10.3390/nu12061657.

38. Theodoreson M.D., Aithal G. P., Allison M., et al. Extra-hepatic morbidity and mortality in alcohol-related liver disease: Systematic review and meta-analysis. Liver Int. 2023 Jan 24. doi: 10.1111/liv.15526.

39. Osna N. A., Rasineni K., Ganesan M., et al. Pathogenesis of Alcohol-Associated Liver Disease. J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1492-1513. doi: 10.1016/j.jceh.2022.05.004.

40. Dukić M., Radonjić T., Jovanović I., et al. Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease.Int J Mol Sci. 2023 Feb 13;24(4):3735. doi: 10.3390/ijms24043735.

41. Seen S. Chronic liver disease and oxidative stress - a narrative review. Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):1021-1035. doi: 10.1080/17474124.2021.1949289.

42. Yang Y. M., Cho Y. E., Hwang S. Crosstalk between Oxidative Stress and Inflammatory Liver Injury in the Pathogenesis of Alcoholic Liver Disease.Int J Mol Sci. 2022 Jan 11;23(2):774. doi: 10.3390/ijms23020774.

43. Gopal T., Ai W., Casey C. A., et al. A review of the role of ethanol-induced adipose tissue dysfunction in alcohol-associated liver disease. Alcohol Clin Exp Res. 2021 Oct;45(10):1927-1939. doi: 10.1111/acer.14698.

44. Hyun J. Y., Kim S. K., Yoon S. J., et al. Microbiome-Based Metabolic Therapeutic Approaches in Alcoholic Liver Disease.Int J Mol Sci. 2022 Aug 6;23(15):8749. doi: 10.3390/ijms23158749.

45. Wu X., Fan X., Miyata T., et al. Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease. Annu Rev Pathol. 2023 Jan 24;18:411-438. doi: 10.1146/annurev-pathmechdis-031521-030435.

46. Gao B., Ahmad M. F., Nagy L. E., Tsukamoto H. Inflammatory pathways in alcoholic steatohepatitis. J. Hepatol. 2019, 70, 249-259. doi: 10.1016/j.jhep.2018.10.023.

47. Glaser T., Baiocchi L., Zhou T., et al. Pro-inflammatory signalling and gut-liver axis in non-alcoholic and alcoholic steatohepatitis: Differences and similarities along the path. J. Cell. Mol. Med. 2020, 24, 5955-5965. doi: 10.1111/jcmm.15182.

48. Thanda Han M. A., Pyrsopoulos N. Emerging Therapies for Alcoholic Hepatitis. Clin Liver Dis. 2021 Aug;25(3):603-624. doi: 10.1016/j.cld.2021.03.006.

49. Kouroumalis E, Voumvouraki A., Augoustaki A., Samonakis D. N. Autophagy in liver diseases. World J Hepatol. 2021 Jan 27;13(1):6-65. doi: 10.4254/wjh.v13.i1.6.

50. Zhou J. C., Wang J. L., Ren H. Z., Shi X. L. Autophagy plays a double-edged sword role in liver diseases. J Physiol Bi.ochem. 2022 Feb;78(1):9-17. doi: 10.1007/s13105-021-00844-7.

51. Xu D., Tian Y., Xia Q., Ke B. The cGAS-STING Pathway: Novel Perspectives in Liver Diseases. Front Immunol. 2021 Apr 29;12:682736. doi: 10.3389/fimmu.2021.682736.

52. Wang X., He Y., Mackowiak B., Gao B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut. 2021 Apr;70(4):784-795. doi: 10.1136/gutjnl-2020-322526.

53. Tadokoro T., Morishita A., Masaki T. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA.Int J Mol Sci. 2021 Jul 29;22(15):8139. doi: 10.3390/ijms22158139.

54. Nishikawa H., Fukunishi S., Asai A., et al. Dysbiosis and liver diseases (Review).Int J Mol Med. 2021 Sep;48(3):183. doi: 10.3892/ijmm.2021.5016.

55. Xu M., Luo K., Li J., et al. Role of Intestinal Microbes in Chronic Liver Diseases.Int J Mol Sci. 2022 Oct 21;23(20):12661. doi: 10.3390/ijms232012661.

56. Liu J., Yang D., Wang X., et al. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol. 2022 Apr 4;12:774335. doi: 10.3389/fcimb.2022.774335.

57. Fairfield B., Schnabl B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 2020 Dec 10;3(2):100220. doi: 10.1016/j.jhepr.2020.100220.

58. Jung J. H., Kim S. E., Suk K. T., Kim D. J. Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota. Front Med (Lausanne). 2022 Jul 22;9:913842. doi: 10.3389/fmed.2022.913842.

59. Farooqui N., Elhence A., Shalimar. A Current Understanding of Bile Acids in Chronic Liver Disease. J Clin Exp Hepatol. 2022 Jan-Feb;12(1):155-173. doi: 10.1016/j.jceh.2021.08.017.

60. Maccioni L., Leclercq I. A., Schnabl B., Stärkel P. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.Int J Mol Sci. 2021 Nov 24;22(23):12687. doi: 10.3390/ijms222312687.

61. Trebicka J., Macnaughtan J., Schnabl B., et al. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021 Jul;75 Suppl 1(Suppl 1): S67-S81. doi: 10.1016/j.jhep.2020.11.013.

62. Liu J., Yang D., Wang X., et al. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol. 2022 Apr 4;12:774335. doi: 10.3389/fcimb.2022.774335.

63. Manzoor R., Ahmed W., Afify N., et al. Trust Your Gut: The Association of Gut Microbiota and Liver Disease. Microorganisms. 2022 May 18;10(5):1045. doi: 10.3390/microorganisms10051045.

64. Rattan P., Shah V. H. Review article: current and emerging therapies for acute alcohol-associated hepatitis. Aliment Pharmacol Ther. 2022 Jul;56(1):28-40. doi: 10.1111/apt.16969.

65. Ayares G., Idalsoaga F., Díaz L. A., et al. Current Medical Treatment for Alcohol-Associated Liver Disease. J Clin Exp Hepatol. 2022 Sep-Oct;12(5):1333-1348. doi: 10.1016/j.jceh.2022.02.001.

66. Wakil A., Niazi M., Meybodi M. A., Pyrsopoulos N. T. Emerging Pharmacotherapies in Alcohol-Associated Hepatitis. J Clin Exp Hepatol. 2023 Jan-Feb;13(1):116-126. doi: 10.1016/j.jceh.2022.06.012.

67. Cabezas J. Management of Alcohol-Related Liver Disease and Its Complications. Clin Drug Investig. 2022 Jun;42(Suppl 1):47-53. doi: 10.1007/s40261-022-01143-9.

68. Thursz M. R., Richardson P., Allison M, et al.; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Apr 23;372(17):1619-1628. doi: 10.1056/NEJMoa1412278.

69. Gougol A., Clemente-Sanchez A., Argemi J., Bataller R. Alcoholic Hepatitis. Clin Liver Dis (Hoboken). 2021 Sep 19;18(2):90-95. doi: 10.1002/cld.1092.

70. Kaur B., Rosenblatt R., Sundaram V. Infections in Alcoholic Hepatitis. J Clin Transl Hepatol. 2022 Aug 28;10(4):718-725. doi: 10.14218/JCTH.2022.00024.

71. German M. N., Musto J., Lucey M. R. Novel treatments for alcoholic hepatitis. Curr Opin Gastroenterol. 2021 May 1; 37(3): 179-186. doi: 10.1097/MOG.0000000000000725.

72. Kedarisetty C. K., Kumar A., Sarin S. K. Insights into the Role of Granulocyte Colony-Stimulating Factor in Severe Alcoholic Hepatitis. Semin Liver Dis. 2021 Jan;41(1):67-78. doi: 10.1055/s-0040-1719177.

73. Rathi S., Hussaini T., Yoshida E. M. Granulocyte colony stimulating factor: A potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis. Ann Hepatol. 2021 Jan-Feb;20:100211. doi: 10.1016/j.aohep.2020.04.011.

74. Maddur H. Current Therapies for Alcohol-Associated Hepatitis. Clin Liver Dis. 2021 Aug;25(3):595-602. doi: 10.1016/j.cld.2021.03.005.

75. Marot A., Singal A. K., Moreno C., Deltenre P. Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials. JHEP Rep. 2020 Jun 18;2(5):100139. doi: 10.1016/j.jhepr.2020.100139.

76. Isac T., Isac S., Rababoc R., et al. Epigenetics in inflammatory liver diseases: A clinical perspective (Review). Exp Ther Med. 2022 May;23(5):366. doi: 10.3892/etm.2022.11293